Caris Diagnostics Adds Leading Oncologist to Team of Personalized Medicine Experts

IRVING, Texas and PHOENIX, May 27, 2009 (GLOBE NEWSWIRE) -- Caris Diagnostics
(Caris Dx) -- a leading provider of integrated anatomic pathology and oncology
testing services, including molecular profiling and hematopathology -- today
announced the appointment of a nationally-renowned oncologist, David Loesch, MD,
as Director of Oncology, Clinical Trials and Services.

"Dr. Loesch has been a recognized leader in the oncology community for years,
with a firm commitment to personalized care and oncology research. He will be
instrumental to our goal of becoming the trusted provider of molecular profiling
for cancer patients," says David D. Halbert, Chairman and CEO of Caris Dx. "The
appointment of Dr. Loesch provides further evidence of our organizational
commitment to the oncology market, as Caris Dx begins to define the future of
individualized oncology care."

Loesch is widely recognized as one of the nation's foremost authorities on
breast cancer diagnosis, treatment and research. He has served as Co-Chairman of
the Breast Cancer Committee for the US Oncology (USO) Network and has been a
practicing medical oncologist for over 18 years. In 2006, he was bestowed the
Indiana Breast Cancer Alliance (IBCA) Medical Researcher "Excellence" Award and
in 2007 was named the Indiana Breast Cancer Researcher of the Year by the
Indiana Breast Cancer Coalition.

"This is an exciting time for Caris Dx, my clinical colleagues, and myself, as
the field of clinical oncology rapidly shifts towards the molecular paradigm,"
Loesch says. "I look forward to helping Caris Dx develop our next generation
Target Now(r) oncology testing service and strategically position ourselves to
build one of the most robust and integrated molecular testing programs in the
nation."

About Caris Diagnostics

Caris Dx is a U.S. based biosciences company specializing in development and
commercialization of clinically-validated molecular diagnostics and anatomic
pathology services primarily in the fields of oncology, dermatopathology,
hematopathology and gastrointestinal pathology. The company provides
academic-caliber medical consults through its industry-leading team of
subspecialty fellowships and expert-trained pathologists in gastrointestinal and
liver pathology, dermatopathology and hematopathology. Caris Dx also offers
advanced molecular analyses of patient samples through prognostic testing
services and genomic and proteomic profiling to assist physicians in their
treatment of cancer and other complex diseases. Currently, Caris Dx receives and
analyzes biopsies for more than 2,700 patients per day, referred by more than
2,500 physicians nationally. Formed in 1996, the company is headquartered in
Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2
sites) and Newton, Massachusetts. Additional information is available at
www.carisdx.com.

-0-
CONTACT: Caris Diagnostics
Michael Guidotti, Senior Vice President Marketing
(214) 596-7406
mguidotti@carisdx.com

Perry Street Communications
Alex Wolfe
(214) 965-9955
awolfe@perryst.com